Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated
with Cabozantinib

J 2020

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA et. al.

Basic information

Original name

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

Authors

BÜCHLER, Tomáš (203 Czech Republic, guarantor), Marie KOPECKA (203 Czech Republic), Anezka ZEMANKOVA (203 Czech Republic), Marketa WIESNEROVA (203 Czech Republic), Marketa STRECKOVA (203 Czech Republic), Aneta ROZSYPALOVA (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, belonging to the institution) and Igor RICHTER (203 Czech Republic)

Edition

Targeted Oncology, Dordrecht, Springer, 2020, 1776-2596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.493

RIV identification code

RIV/00216224:14110/20:00116254

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11523-020-00744-8

UT WoS

000555352100001

Keywords in English

Sarcopenia; Metastatic Renal Cell Carcinoma; Cabozantinib

Abstract

V originále

Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. Results The median muscle mass index at CT1 and CT2 was 52.2 cm(2)/m(2)(range 33.0-69.2 cm(2)/m(2)) and 49.1 cm(2)/m(2)(range 33.1-68.2 cm(2)/m(2)), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm(2)/m(2)(range - 10.1 to + 4.8cm(2)/m(2)). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p= 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. Conclusions Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.

Citovat

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA, Aneta ROZSYPALOVA, Bohuslav MELICHAR, Alexandr POPRACH and Igor RICHTER. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. Targeted Oncology. Dordrecht: Springer, 2020, vol. 15, No 5, p. 673-679. ISSN 1776-2596. Available from: https://dx.doi.org/10.1007/s11523-020-00744-8.

@article{1674863,
   author = {Büchler, Tomáš and Kopecka, Marie and Zemankova, Anezka and Wiesnerova, Marketa and Streckova, Marketa and Rozsypalova, Aneta and Melichar, Bohuslav and Poprach, Alexandr and Richter, Igor},
   article_location = {Dordrecht},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s11523-020-00744-8},
   keywords = {Sarcopenia; Metastatic Renal Cell Carcinoma; Cabozantinib},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib},
   url = {https://link.springer.com/article/10.1007%2Fs11523-020-00744-8},
   volume = {15},
   year = {2020}
}

TY  - JOUR
ID  - 1674863
AU  - Büchler, Tomáš - Kopecka, Marie - Zemankova, Anezka - Wiesnerova, Marketa - Streckova, Marketa - Rozsypalova, Aneta - Melichar, Bohuslav - Poprach, Alexandr - Richter, Igor
PY  - 2020
TI  - Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
JF  - Targeted Oncology
VL  - 15
IS  - 5
SP  - 673-679
EP  - 673-679
PB  - Springer
SN  - 17762596
KW  - Sarcopenia
KW  - Metastatic Renal Cell Carcinoma
KW  - Cabozantinib
UR  - https://link.springer.com/article/10.1007%2Fs11523-020-00744-8
L2  - https://link.springer.com/article/10.1007%2Fs11523-020-00744-8
N2  - Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. Results The median muscle mass index at CT1 and CT2 was 52.2 cm(2)/m(2)(range 33.0-69.2 cm(2)/m(2)) and 49.1 cm(2)/m(2)(range 33.1-68.2 cm(2)/m(2)), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm(2)/m(2)(range - 10.1 to + 4.8cm(2)/m(2)). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p= 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. Conclusions Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.
ER  -

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA, Aneta ROZSYPALOVA, Bohuslav MELICHAR, Alexandr POPRACH and Igor RICHTER. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. \textit{Targeted Oncology}. Dordrecht: Springer, 2020, vol.~15, No~5, p.~673-679. ISSN~1776-2596. Available from: https://dx.doi.org/10.1007/s11523-020-00744-8.

Detailed Information on Publication Record